Platform·Healthcare/Medical Devices·July 7, 2026
EQT acquires Corza Medical's biosurgery business
The carveout includes TachoSil, a fibrin sealant patch used to control bleeding during surgery.
Takeaways
- Its Biosurgery Business Unit is a developer and marketer of TachoSil, a fibrin sealant patch used to control bleeding and seal tissue during surgical procedures.
- EQT is acquiring Its Biosurgery Business Unit.
- The business serves healthcare providers performing surgical procedures.
BuyerEQT
TargetCorza Medical's Biosurgery business unit
SponsorEQT
SellerGTCR
TypePlatform
IndustryHealthcare
Sub-sectorMedical Devices
EQT agreed to acquire Corza Medical’s biosurgery business, including TachoSil, a fibrin sealant patch used to control bleeding during surgery.
The unit is being carved out of GTCR-backed Corza Medical, which will retain its wound closure, ophthalmology and biomedical textiles businesses.
EQT plans to establish the biosurgery business as a standalone healthcare platform.
Terms were not disclosed.
Daily PE deal brief
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.